Skip to content

Subscription

Turn on notifications to stay up to date with new posts.

A startup founded by a Harvard professor has received FDA approval to test a drug against cellular aging

Life Biosciences, founded by Harvard genetics professor David Sinclair, has received FDA approval for clinical trials of a drug that, for the first time in medical history, attempts to reverse human cell aging. In June 2026, the first patient already received a dose. Let's examine what exactly is happening and why this is important.

Published 3 min read
T

Author - The Tech

A startup founded by a Harvard professor has received FDA approval to test a drug against cellular aging

The Tech AI

Get the key points in seconds - a short summary from The Tech AI.

On January 28, 2026, Life Biosciences received FDA approval to conduct clinical trials of ER-100, the first therapy based on epigenetic cell reprogramming for humans. The treatment is intended for the management of open-angle glaucoma and acute optic neuropathy, conditions in which vision loss is irreversible. On June 9, 2026, the first dose was administered to a patient, and in April of the same year, the company secured $80 million in funding.

The Tech on Telegram

Keep up with the latest technology and startup news.

Subscribe
News Courses Events Jobs Podcasts

Loading next post…